Brief: Inify Laboratories Q4 EBITDA Loss At SEK 19.9 Mln
25/02/2026 07:10
Feb 25 (Reuters) - INIFY Laboratories AB INIFY.OL: INIFY LABORATORIES: SOLID TOPLINE GROWTH, STRONG UK DEVELOPMENT, AND POSITIVE RESPONSE TO GASTROINTESTINAL DIAGNOSTICS Q4 EBITDA LOSS SEK 19.9 MILLION Q4 SALES SEK 6.5 MILLION BOARD OF DIRECTORS DOES NOT PROPOSE ORDINARY DIVIDEND FOR 2025 Source text: ID:nObiKbT96a Further company coverage: INIFY.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on INIFY Laboratories AB
See all newsBrief: Inify Laboratories Signs Deal With University Hospitals Plymouth NHS Trust
Brief: Inify Laboratories Gets CQC Registration, Is Fully Operational In UK
Brief: Inify Laboratories Q1 Sales Up At SEK 6.3 Mln
Brief: Inify Laboratories Signs Agreement With Region Jämtland Härjedalen
Brief: Inify Laboratories Has Signed An Agreement With Region Jamtland Harjedalen For Prostate Cancer Diagnostics